摘要
目的:探讨躯体形式障碍患者的有效治疗方法及安全性。方法:60例躯体形式障碍患者随机分为A组与B组各30例,均采用帕罗西汀片治疗,A组同时加服氟哌噻吨美利曲辛片,共治疗8周。治疗前和治疗后第2、4、6、8周末分别采用汉密顿抑郁量表(HAMD)、汉密顿焦虑量表(HAMA)、副反应量表(TESS)评分。结果:与治疗前比较,治疗2、4周时HAMD、HAMA评分,A组明显下降(P<0.01),治疗4周时B组开始明显下降(P<0.001);治疗8周时2组均显著下降(P<0.01)。2组患者出现副反应轻微,无因药物反应而中断治疗,安全性良好。结论:帕罗西汀与氟哌噻吨美利曲辛治疗躯体形式障碍的疗效及安全性类似,但帕罗西汀合并氟哌噻吨美利曲辛治疗躯体形式障碍则起效更快。
Objective： To study the effectiveness and safety of combined use of Paroxetine and Deanxit treating somatoform disorders （SD）. Methods： Sixty patients with SD were randomly divided into a combined group with 30 patients treated by Paroxetine and Deanxit, and a control group with 30 patients treated by Paroxetine. The treatment lasted for 8 weeks. The HAMA, HAMD and the TESS were used to assess the anxiety, depression and the side effects before and 2, 4, 6, 8 weeks after treatment. Results： The scores of HAMD and HAMA in the combined group were significantly lower than those in the control group after treatment for 2 weeks. The scores of HAMD and HAMA in control group were declined significantly after treatment for 4 weeks. The scores of HAMD and HAMA were decreased significantly in both groups （P〈0.01）, with slight side effects. None of the patients quitted treatment because of the side effects. Conclusion： There were no significant differences in the effectiveness and safety between the combined group and the control group, however, the combined use of Paroxetine and Deanxit obtained effectiveness more quickly in treating SD.
出处
《中国康复》
2006年第6期388-389,共2页
Chinese Journal of Rehabilitation
